333 related articles for article (PubMed ID: 21615387)
1. The histamine H3 receptor: from discovery to clinical trials with pitolisant.
Schwartz JC
Br J Pharmacol; 2011 Jun; 163(4):713-21. PubMed ID: 21615387
[TBL] [Abstract][Full Text] [Related]
2. Role of the Histamine H
Schlicker E; Kathmann M
Handb Exp Pharmacol; 2017; 241():277-299. PubMed ID: 27787717
[TBL] [Abstract][Full Text] [Related]
3. BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology.
Ligneau X; Perrin D; Landais L; Camelin JC; Calmels TP; Berrebi-Bertrand I; Lecomte JM; Parmentier R; Anaclet C; Lin JS; Bertaina-Anglade V; la Rochelle CD; d'Aniello F; Rouleau A; Gbahou F; Arrang JM; Ganellin CR; Stark H; Schunack W; Schwartz JC
J Pharmacol Exp Ther; 2007 Jan; 320(1):365-75. PubMed ID: 17005916
[TBL] [Abstract][Full Text] [Related]
4. Pitolisant for treating patients with narcolepsy.
Li S; Yang J
Expert Rev Clin Pharmacol; 2020 Feb; 13(2):79-84. PubMed ID: 31937172
[No Abstract] [Full Text] [Related]
5. Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness.
Inocente C; Arnulf I; Bastuji H; Thibault-Stoll A; Raoux A; Reimão R; Lin JS; Franco P
Clin Neuropharmacol; 2012; 35(2):55-60. PubMed ID: 22356925
[TBL] [Abstract][Full Text] [Related]
6. Pitolisant (Wakix) for narcolepsy.
Med Lett Drugs Ther; 2021 Feb; 63(1617):19-21. PubMed ID: 33647004
[No Abstract] [Full Text] [Related]
7. A Novel Potent and Selective Histamine H
Hino N; Marumo T; Kotani M; Shimazaki T; Kaku-Fukumoto A; Hikichi H; Karasawa JI; Tomishima Y; Komiyama H; Tatsuda E; Nozawa D; Nakamura T; Chaki S
J Pharmacol Exp Ther; 2020 Nov; 375(2):276-285. PubMed ID: 32862143
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of the abuse potential of Pitolisant, a histamine H₃ receptor inverse agonist/antagonist compared with Modafinil.
Uguen M; Perrin D; Belliard S; Ligneau X; Beardsley PM; Lecomte JM; Schwartz JC
Br J Pharmacol; 2013 Jun; 169(3):632-44. PubMed ID: 23472741
[TBL] [Abstract][Full Text] [Related]
9. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders.
Parmentier R; Anaclet C; Guhennec C; Brousseau E; Bricout D; Giboulot T; Bozyczko-Coyne D; Spiegel K; Ohtsu H; Williams M; Lin JS
Biochem Pharmacol; 2007 Apr; 73(8):1157-71. PubMed ID: 17288995
[TBL] [Abstract][Full Text] [Related]
10. Effects of histamine H3 receptor ligands in experimental models of anxiety and depression.
Pérez-García C; Morales L; Cano MV; Sancho I; Alguacil LF
Psychopharmacology (Berl); 1999 Feb; 142(2):215-20. PubMed ID: 10102775
[TBL] [Abstract][Full Text] [Related]
11. Role of Histamine H
Xu G; Liu N; Qiu Y; Qi J; Zhu D
Stem Cells Dev; 2024 Feb; 33(3-4):67-78. PubMed ID: 38032751
[TBL] [Abstract][Full Text] [Related]
12. Thioperamide, a selective histamine H3 receptor antagonist, protects against PTZ-induced seizures in mice.
Vohora D; Pal SN; Pillai KK
Life Sci; 2000 Apr; 66(22):PL297-301. PubMed ID: 10834305
[TBL] [Abstract][Full Text] [Related]
13. Histamine and selective H3-receptor ligands: a possible role in the mechanism and management of epilepsy.
Vohora D; Pal SN; Pillai KK
Pharmacol Biochem Behav; 2001 Apr; 68(4):735-41. PubMed ID: 11526971
[TBL] [Abstract][Full Text] [Related]
14. [The histamine H(3) receptor: a target for new drugs].
Arrang JM
Ann Pharm Fr; 2003 May; 61(3):173-84. PubMed ID: 12714930
[TBL] [Abstract][Full Text] [Related]
15. Potentiation of the discriminative-stimulus effects of methamphetamine by the histamine H3 receptor antagonist thioperamide in rats.
Munzar P; Nosál R; Goldberg SR
Eur J Pharmacol; 1998 Dec; 363(2-3):93-101. PubMed ID: 9881573
[TBL] [Abstract][Full Text] [Related]
16. Several down, a few to go: histamine H3 receptor ligands making the final push towards the market?
Kuhne S; Wijtmans M; Lim HD; Leurs R; de Esch IJ
Expert Opin Investig Drugs; 2011 Dec; 20(12):1629-48. PubMed ID: 21992603
[TBL] [Abstract][Full Text] [Related]
17. Brain histamine and schizophrenia: potential therapeutic applications of H3-receptor inverse agonists studied with BF2.649.
Ligneau X; Landais L; Perrin D; Piriou J; Uguen M; Denis E; Robert P; Parmentier R; Anaclet C; Lin JS; Burban A; Arrang JM; Schwartz JC
Biochem Pharmacol; 2007 Apr; 73(8):1215-24. PubMed ID: 17343831
[TBL] [Abstract][Full Text] [Related]
18. The histamine H₃-receptor inverse agonist pitolisant improves fear memory in mice.
Brabant C; Charlier Y; Tirelli E
Behav Brain Res; 2013 Apr; 243():199-204. PubMed ID: 23327739
[TBL] [Abstract][Full Text] [Related]
19. Histamine H3 receptor agonist- and antagonist-evoked vacuous chewing movements in 6-OHDA-lesioned rats occurs in an absence of change in microdialysate dopamine levels.
Nowak P; Dabrowska J; Bortel A; Biedka I; Szczerbak G; Słomian G; Kostrzewa RM; Brus R
Eur J Pharmacol; 2006 Dec; 552(1-3):46-54. PubMed ID: 17055481
[TBL] [Abstract][Full Text] [Related]
20. Pitolisant: First Global Approval.
Syed YY
Drugs; 2016 Sep; 76(13):1313-1318. PubMed ID: 27438291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
